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OBJECTIVES Prophylactic acetylcysteine along with hydration seems to be better than hydration alone in
preventing the reduction in renal function induced by a contrast dye.
BACKGROUND Contrast media can lead to acute renal failure that may occasionally require hemodialysis.
METHODS One hundred eighty-three consecutive patients with impairment of renal function, undergo-
ing coronary and/or peripheral angiography and/or angioplasty, were randomly assigned to
receive 0.45% saline intravenously and acetylcysteine (600 mg orally twice daily; group A, n
92) or 0.45% saline intravenously alone (group B, n  91) before and after nonionic,
low-osmolality contrast dye administration.
RESULTS The baseline serum creatinine concentrations were similar (1.5  0.4 mg/dl in group A vs.
1.5  0.4 mg/dl in group B; p  0.37). An increase of 25% in the baseline creatinine level
48 h after the procedure occurred in 6 (6.5%) of 92 patients in group A and in 10 (11%) of
91 patients in group B (p 0.22). In the subgroup with a low (140 ml) contrast dose, renal
function deterioration occurred in 5 (8.5%) of 60 patients in group B and in 0 of 60 patients
in group A (p  0.02; odds ratio [OR] 0.44, 95% confidence interval [CI] 0.35 to 0.54). In
the subgroup with a high contrast dose, no difference was found (5/31 vs. 6/32 patients, p 
0.78). By multivariate analysis, the amount of contrast agent, but not the treatment strategy,
was a predictor of the occurrence of contrast dye–associated nephrotoxicity (OR 2.58, 95% CI
1.1 to 4.9; p  0.035).
CONCLUSIONS In patients with reduced renal function undergoing angiography and/or angioplasty, the
amount of contrast agent, but not the administration of prophylactic acetylcysteine, was a
predictor of renal function deterioration. Prophylactic acetylcysteine might provide better
protection than hydration alone, only when a small volume of contrast agent is used. (J Am
Coll Cardiol 2002;40:298–303) © 2002 by the American College of Cardiology Foundation
Radiocontrast media can lead to a reversible form of acute
renal failure that begins soon after contrast dye administra-
tion and that is generally benign (1). However, especially in
high-risk patients, transient dialysis may be required. This
renal failure requiring dialysis after a coronary intervention
is associated with poor outcomes, including 40% in-hospital
mortality and 19% two-year survival (2–4). The mechanism
by which contrast-induced renal failure occurs is not well
known. The two major theories, based largely on studies in
experimental animals, are renal vasoconstriction, possibly
mediated by an alteration in nitric oxide and/or endothelin,
and direct toxic effects of the contrast agents (5–10).
The ability to more effectively prevent contrast-associated
nephrotoxicity in high-risk patients will result in significant
public health benefits by reducing in-hospital mortality, the
hospital stay and the need for dialysis. Periprocedural
hydration (11) and the use of a small amount of low-
osmolality contrast agent (12–15) are generally considered
worldwide in patients at risk of contrast-associated nephro-
toxicity. Recently, Tepel et al. (16) reported that
N-acetylcysteine along with hydration is more effective than
hydration alone in preventing contrast-associated nephro-
toxicity in patients with chronic renal insufficiency treated
with an intravenous contrast dye. In the present study, we
sought to demonstrate the efficacy of such a strategy in
patients with impairment of renal function who were
referred to our institution for coronary and/or peripheral
angiography and/or angioplasty.
METHODS
Patient group. From September 2000, 183 consecutive
patients with impairment of renal function (serum creati-
nine concentration 1.2 mg/dl and/or estimated creatinine
clearance 70 ml/min) were referred to our institution to
undergo elective coronary and/or peripheral angiography
and/or angioplasty. Patients were randomly assigned to
receive the antioxidant acetylcysteine and intravenous saline
before and after administration of the contrast agent (group
A) or saline alone (group B). Acetylcysteine was given orally
at a dose of 600 mg twice daily, on the day before and on the
day of administration of the contrast agent, for a total of two
days. Saline (0.45%) was given intravenously at a rate of
1 ml/kg body weight per hour for 12 h before and 12 h after
administration of the contrast agent (11). Iopromide
(Ultravist-370, 0.769 mg/ml, 370 mg iodine/ml; Schering,
Berlin, Germany), a nonionic, low-osmolality contrast
agent, was used. None of the patients received theophylline,
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dopamine, mannitol or furosemide during the study. Serum
creatinine and urea nitrogen levels were measured immedi-
ately before and 48 h after administration of the contrast
agent; further measurements were performed in all cases of
contrast-associated nephrotoxicity. Creatinine clearance
(CrCl) was calculated by applying the Cockcroft-Gault
formula to the baseline serum creatinine level: CrCl 
([140 age] weight/serum creatinine 72), with female
gender adjustment: CrClfemale  CrCl  0.85 (17). Pro-
teinuria was determined by urinalysis (immunometric assay,
NycoCard U-Albumin, Axus-Schiled PoCAS, Oslo, Nor-
way) the day before contrast agent administration (18).
Proteinuria is traditionally divided into microalbuminuria
and macroalbuminuria. Microalbuminuria is defined as a
protein excretion of 30 to 300 mg/24 h. Macroalbuminuria
is defined as a protein excretion of 300 mg/24 h. An early
contrast agent-induced reduction in renal function was
defined as an increase in the serum creatinine concentration
of25% of the baseline value at 48 h or the need for dialysis
after administration of the contrast media (8,15). Acute
renal failure requiring dialysis was defined as a decrease in
renal function necessitating immediate hemodialysis, ultra-
filtration or peritoneal dialysis in the first five days after the
intervention. The local ethics committee approved the study
protocol, and all patients gave written, informed consent.
Statistical analysis. Continuous variables are given as the
mean value  SD. The unpaired Student t test was
performed to determine differences between mean values for
continuous variables, as appropriate. Creatinine and pro-
teinuria concentrations were not normally distributed;
therefore, the nonparametric Wilcoxon and Mann-Whitney
U tests assessed intragroup and intergroup differences,
respectively. Categorical variables were analyzed by the
chi-square test. Changes in the serum creatinine concentra-
tion from baseline between groups were tested by two-way
repeated measures analysis of variance, with the treatment
strategy (as defined in groups A and B), time period and
time  treatment strategy interaction as fixed effects and
patient as a random effect. Receiver operating characteristic
(ROC) curve analysis was performed to establish the value
of the contrast volume most predictive of an early contrast
agent-induced reduction in renal function. Multiple logistic
regression was performed with the early contrast agent-
induced reduction in renal function as the dependent
variable. The treatment strategy (as defined in groups A and
B) and the amount of contrast dye were entered into the
multivariable model to test for independent effects. Proba-
bility values 0.05 were considered significant. Data were
analyzed with SPSS for Windows, release 10.0 (SPSS Inc.,
Chicago, Illinois).
RESULTS
Clinical characteristics. The clinical and biochemical
characteristics of the patients in the two groups are shown in
Tables 1 and 2. One hundred three patients underwent
coronary angiography, with an eventual (ad-hoc) percuta-
neous coronary intervention (PCI) in 22 of the patients.
Fifty-six patients underwent elective PCI. The remaining
11 patients had angiography for peripheral artery disease.
Amount of contrast agent. The amount of contrast agent
administered was similar between the two groups (194 
127 ml in group A vs. 200  144 ml in group B; p  0.80).
Of note, the amount of contrast dye was significantly higher
in patients who had ad-hoc PCI (347  182 ml vs. 321 
125 ml for PCI alone, 135  72 ml for coronary angiog-
raphy alone and 114  43 ml for peripheral angiography;
p  0.001).
Abbreviations and Acronyms
CI  confidence interval
CrCl  creatinine clearance
OR  odds ratio
PCI  percutaneous coronary intervention
ROC  receiver operating characteristic




(n  91) p Value
Age (yrs) 64  9 64  9 0.97
Male gender 77 (84%) 81 (89%) 0.35
Body mass index (g/m2) 28  5 28  4 0.95
Blood pressure (mm Hg)
Systolic 133  16 130  18 0.27
Diastolic 79  8 77  8 0.25
Mean 71  16 72  21 0.55
Left ventricular ejection
fraction (%)
51  13 54  12 0.16
Hypertension 66 (72%) 65 (72%) 0.46
Diabetes mellitus 40 (43%) 29 (32.5%) 0.10
Hypercholesterolemia 138 (52%) 97 (56%) 0.70
Coronary artery disease 82 (89%) 80 (88%) 0.69
Single-vessel 25 (30.5%) 19 (23.8%)
Double-vessel 21 (25.6%) 26 (32.5%)
Triple-vessel 36 (43.9%) 35 (43.7%)
Data are presented as the mean value  SD or number (%) of patients.




(n  91) p Value
Serum creatinine (mg/dl)
Baseline 1.52  0.43 1.54  0.36 0.37
After 48 h 1.48  0.36 1.53  0.45 0.55
Clearance creatinine (ml/min) 56  22 54  16 0.82
Proteinuria (mg/24 h) 214  433 110  142 0.40
Macroalbuminuria* (mg/24 h) 12.5% 13% 0.94
Serum urea nitrogen (mg/dl) 56  22 54  16 0.66
Serum sodium (mEq/l) 142  4 142  4 0.84
Serum potassium (mEq/l) 4.8  0.6 4.8  0.5 0.86
Drugs assumed
ACE inhibitors 52 (56.5%) 60 (55%) 0.84
Calcium antagonists 33 (36.2%) 42 (38.4%) 0.92
AT-II antagonists 12 (13%) 8 (7%) 0.21
Diuretics 31 (33.7%) 42 (38%) 0.57
*Protein excretion 300 mg/24 h. Data are presented as the mean value  SD or
number (%) of patients.
ACE  angiotensin-converting enzyme; AT-II  angiotensin II.
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Contrast agent-associated nephrotoxicity. The mean se-
rum creatinine concentration for all patients was 1.52 
0.40 mg/dl (range 1.25 to 4.84 mg/dl). In group A, the
mean serum creatinine concentration decreased from
1.52  0.43 mg/dl (range 1.25 to 4.84) to 1.48 
0.36 mg/dl 48 h after contrast agent administration (Fig. 1).
In group B, the mean serum creatinine concentration
decreased from 1.54  0.36 mg/dl (range 1.26 to 3.20) to
1.53  0.46 mg/dl (Fig. 1). There was no statistically
significant interaction between the changes in serum creat-
inine concentration from baseline and the treatment strat-
egy (F  0.026, p 0.87) (Fig. 1).
Acute contrast agent-associated nephrotoxicity occurred
in 6 (6.5%) of 92 patients in group A and in 10 (11%) of 91
patients in group B (p  0.22). Renal failure requiring
temporary dialysis occurred in only one patient in group B
(1.1%).
The amount of contrast agent, even thought slightly
higher in group A, was not statistically different in the 16
patients of the two groups who had contrast agent-
associated nephrotoxicity (348  159 ml in group A and
192  115 ml in group B; p  0.15). We found a
significant, direct correlation between the absolute change
in serum creatinine concentration and the amount of con-
trast agent in group A only (r  0.42, p  0.001) (Fig. 2),
but not in group B (r  0.07, p  0.59). By ROC analysis,
we identified a contrast media volume 140 ml as the best
cutoff value to predict the occurrence of contrast-associated
nephrotoxicity (sensitivity 89%, specificity 55%). In the
subgroup with a small (140 ml) contrast dose, significant
renal function deterioration occurred in 5 (8.5%) of 60
patients in group B and in none in group A (p  0.020;
odds ratio [OR] 0.44, 95% confidence interval [CI] 0.35 to
0.54). In the subgroup with a high (140 ml) contrast dose,
the event occurred in 5 (16%) of 31 patients in group B and
in 6 (18.8%) of 32 patients in group A (p  0.78).
Proteinuria levels and the macroalbuminuria rate were
similar in patients with and without contrast-associated
nephrotoxicity (138 123 mg/24 h vs. 163 318 mg/24 h,
p  0.66; and 13% vs. 12.5%, p  0.94, respectively).
A baseline serum creatinine concentration above 1.8 mg/dl
occurred in 31 patients (34%) in group A and in 33 patients
(36%) in group B (p  0.27). Among these patients, two in
group A (6.5%) and six in group B (18%) had an early
contrast agent-induced reduction in renal function (p 
0.16). Importantly, among the subgroup of patients who
received a low amount of contrast agent (13/31 in group A
and 16/33 in group B; p  0.6), none of the 13 patients in
group A had acute renal function impairment, although this
complication occurred in 4 (25%) of the 16 patients in group
B (p  0.049; OR 0.75, 95% CI 0.56 to 0.99). In contrast,
there was no significant difference when a high volume of
contrast dye was administered (2/18 in group A vs. 2/17 in
group B; p  0.15).
By logistic regression analysis, the amount of contrast
agent administered (OR 2.58, 95% CI 1.1 to 4.9; p 
0.035), but not the treatment strategy (as defined in groups
A and B) (OR 0.6, 95% CI 0.18 to 2.02; p  0.41), was a
predictor of acute renal function deterioration.
DISCUSSION
Radiographic contrast media account for 10% of all causes
of hospital-acquired acute renal failure and represent the
third most common cause of in-hospital renal function
deterioration after decreased renal perfusion and postoper-
ative renal insufficiency (19). Persistent renal failure is rare
and has been described primarily with far-advanced under-
lying disease (2–4). The in-hospital mortality rate in pa-
tients developing renal insufficiency is directly related to the
magnitude of the increase in the serum creatinine concen-
tration (2–4). The mortality rate ranges from 3.8% with an
increase in serum creatinine of 0.5 to 0.9 mg/dl to 64% with
an increase of 3.0 mg/dl (20). The ability to more
effectively prevent contrast-associated nephrotoxicity in
high-risk patients will provide significant public health
Figure 1. Serum creatinine concentration at baseline (solid bar) and at 48 h (open bar) after contrast dye administration in patients treated with
acetylcysteine and hydration (Acetylcysteine Group) and in those treated with hydration alone (Control Group). Brackets represent the standard deviation.
There was no statistically significant interaction between the changes in the serum creatinine concentration from baseline and the treatment strategy (F 
0.026, p  0.87) by the two-way analysis of variance for repeated measures.
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benefits as we reduce the in-hospital mortality rates, hospi-
tal stay and need for dialysis.
The main results of the present study are: 1) the most
important predictor of contrast dye-associated nephrotoxic-
ity is the amount of contrast dye administered; and 2)
prophylactic administration of saline and acetylcysteine
might be more effective than saline alone in preventing
contrast-associated nephrotoxicity only when a small
(140 ml) amount of a nonionic, low-osmolality contrast
dye is used.
Previous studies on prevention of contrast-associated
nephrotoxicity. Optimal therapy to prevent contrast-
associated nephrotoxicity remains uncertain. Trials of pro-
phylactic measures in humans have evaluated hydration
strategies, furosemide, mannitol, dopamine, calcium-
channel blocks and atrial natriuretic peptide (11,21–25). In
general, all of the previous prevention trials have shown no
consistent benefit, and in some cases, a deleterious effect was
seen with the use of dopamine (21,25), mannitol (22),
forced diuresis (22), atrial natriuretic peptide (24) or ami-
nophylline (23,25) for contrast-associated nephrotoxicity.
Solomon et al. (11) showed in a randomized trial that saline
hydration is more effective than saline plus furosemide or
mannitol in preventing an increase in the postprocedural
serum creatinine level. Therefore, at present, only peripro-
cedural hydration (11) and the use of a low-osmolality
contrast agent (12–15) are universally considered in patients
at high risk of contrast-associated nephropathy.
Acetylcysteine and contrast-associated nephrotoxicity.
Considerable enthusiasm has resulted from the preliminary
study by Tepel et al. (16) of acetylcysteine in patients with
chronic renal failure receiving intravenous contrast dye. The
study included 83 patients with a creatinine plasma level
1.2 mg/dl (and/or clearance 50 ml/h) who were under-
going computed tomography with a constant dose of 75 ml
iopromide, a nonionic, low-osmolality contrast agent. These
patients were randomly treated with hydration plus placebo
(n  45) or hydration plus acetylcysteine (600 mg orally
twice daily) before and after administration of the contrast
agent. Ten (12%) of the 83 patients had an increase of at
least 0.5 mg/dl in the serum creatinine concentration 48 h
after administration of the contrast agent: 1 (2%) of the 41
patients in the acetylcysteine group and 9 (21%) of the 42
patients in the control group (p  0.01, relative risk  0.1,
95% CI 0.02 to 0.9). In the acetylcysteine group, the mean
serum creatinine concentration decreased significantly (p 
0.001) from 2.5  1.3 mg/dl to 2.1  1.3 mg/dl at 48 h
after the administration of the contrast medium, whereas in
the control group, the mean serum creatinine concentration
increased nonsignificantly (p  0.18) from 2.4  1.3 mg/dl
to 2.6  1.5 mg/dl.
In our study, we did not find any significant effect on the
occurrence of contrast-associated nephrotoxicity with ace-
tylcysteine treatment. In fact, the occurrence of an increase
of at least 25% of the baseline level in the serum creatinine
concentration 48 h after administration of the contrast agent
Figure 2. Change in creatinine concentration (Crea) from baseline, plotted as a function of the amount of contrast dye administered in the acetylcysteine
group. The horizontal dashed line represents Crea  0; the vertical dashed line represents the cutoff value (140 ml) for small and large amounts of
contrast dye.
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was as follows: 6 (6.5%) of the 92 patients in the acetylcys-
teine group and 10 (11%) of the 91 patients in the control
group (p  0.22). The discordance between our study and
Tepel et al. study (16) may be explained by the differences in
the amount of contrast dye used and in the baseline level of
renal function. In the study by Tepel et al. (16), a constant,
low (75 ml) dose of contrast agent was administered. In
contrast, in our study, the amount of contrast dye used was
variable because of the different type of examination. Im-
portantly, in accordance with Tepel et al. (16), we found a
significant benefit of acetylcysteine administration only in
the subgroup of patients receiving a small (140 ml)
amount of contrast dye. Therefore, it may be that acetyl-
cysteine has a protective effect against contrast-associated
nephrotoxicity only when a low amount of contrast dye is
administered. Furthermore, the baseline mean creatinine
level was higher in the study by Tepel et al. (16) (2.4 
1.3 mg/dl) than in ours. Some data exist that identify the
baseline level of renal function as a predictor of contrast-
induced nephrotoxicity (26).
Potential mechanisms of acetylcysteine’s protective effect.
The mechanism by which contrast-induced renal failure
occurs is not well understood. The two major theories,
based largely on studies in experimental animals, are renal
vasoconstriction and direct toxic effects of the contrast
agents (5–10). Renal vasoconstriction occurs relatively com-
monly; it is mediated in part by contrast-induced release of
endothelin and adenosine, by alterations in nitric oxide and
by the high osmolality of the contrast agent (5–8). The toxic
renal damage may cause tubular injury, leading to the
generation of oxygen free radicals, which are considered as
important modulators of renal blood flow and the glomer-
ular filtration rate (9,10,27,28).
N-acetylcysteine, a reduced thiol, is a precursor of
L-cysteine and may serve as a precursor for glutathione
synthesis. N-acetylcysteine improves endothelium-
dependent vasomotion in the coronary and peripheral cir-
culation (28) and is a potent antioxidant that may scavenge
a wide variety of oxygen-derived free radicals (28–30). The
ability of N-acetylcysteine to increase intracellular and
extracellular glutathione might be a crucial factor in pro-
tecting renal tissue in contrast-induced damage (29). There-
fore, acetylcysteine may be capable to preventing contrast-
associated nephrotoxicity by both improving renal
hemodynamic and preventing direct oxidative tissue dam-
age.
Role of the amount of contrast dye. There is a debate
whether the quantity of the contrast agent predicts the
degree of renal dysfunction. Some studies have reported no
relationship between the amount of contrast material and
the occurrence of renal function deterioration, whereas
others have suggested a direct correlation (31,32). There is,
however, a general consensus on the use of a small dose of
contrast dye, and the avoidance of repetitive, closely spaced
studies represents one of the most important recommenda-
tions to prevent contrast-associated nephrotoxicity (13–15).
A low dose has been variably defined as 70 ml, 125 ml
or 5 ml/kg (to a maximum of 300 ml), divided by the
plasma creatinine concentration (12). McCullough et al. (4)
found that no patient who received100 ml of contrast dye
required dialysis after contrast exposure. In the present
study, the amount of contrast agent administered was an
independent predictor of the occurrence of contrast dye-
associated nephrotoxicity. The main dose for coronary
angiography is 130 ml and that for PCI is 191 ml (33). We
identified a volume of 140 ml as the best cutoff value for
predicting the occurrence of contrast media-associated
nephrotoxicity. These data emphasize the necessity for
limiting the amount of contrast dye used when dealing with
patients with impaired renal function. In particular, the
avoidance of repetitive, closely spaced studies and the
ad-hoc PCI, favoring a staged, or two-step, procedure, may
represent an important strategy to prevent contrast-
associated nephrotoxicity in high-risk patients.
Study limitations. Serum creatinine was only measured
after 48 h. Therefore, we may have missed a later increase in
serum creatinine in some patients who did not have renal
function deterioration within 48 h of their procedure. Our
positive finding—that is, the effectiveness of the combina-
tion of oral acetylcysteine along with hydration only with a
small amount of contrast media—is based on a post-hoc
analysis of a small group of patients. Our results need to be
verified in a larger group of patients with more severe
baseline renal insufficiency.
Conclusions. In patients with reduced renal function un-
dergoing angiography and/or angioplasty, the amount of
contrast agent, but not the prophylactic acetylcysteine treat-
ment, is a predictor of acute renal function deterioration.
Prophylactic acetylcysteine might provide better protection
than hydration alone, only when a small volume of contrast
agent is used.
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